Michael F. Guerrera
Expertise in
12
conditions

Dr. Michael F. Guerrera

Hematology
111 Michigan Ave NW, Dept Of Hematology Oncology, 
Washington, DC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
111 Michigan Ave NW, Dept Of Hematology Oncology, 
Washington, DC 

Overview

Michael F. Guerrera, MD, is the director of the Comprehensive Hemostasis and Thrombosis Program in the Division of Hematology. He served on the Region III Executive Committee for eight years. His clinical interest is in bleeding disorders and general hematology. Dr. Guerrera also has an interest in medical education, was a director of the Hematology Oncology Fellowship Program for eight years and was a participant in the first Children's National Hospital and the George Washington University Master Teacher Program. Dr. Guerrera is the recipient of the 2018 National Hemophilia Foundation Physician of the Year Award.

Dr. Guerrera is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Blood Clots, Hemophilia B, and Hemophilic Arthropathy.

Dr. Guerrera is board certified in Pediatrics: American Board Of Pediatrics, 1998 and Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002. He is actively involved in clinical research, co-authoring 17 peer reviewed articles and participating in 6 clinical trials. Dr. Guerrera is currently accepting new patients.

Specialties

Hematology

Licenses

Pediatrics in VA

Board Certifications

Pediatrics: American Board Of Pediatrics, 1998
Pediatric Hematology-Oncology: American Board Of Pediatrics, 2002

Fellowships

Children's National Hospital, Pediatric Hematology-Oncology - 2001

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Innovation Health
  • HMO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 12 Less Insurance Carriers -

Locations

111 Michigan Ave NW, Dept Of Hematology Oncology, Washington, DC 20010
Other Locations
Pediatric Specialists of Virginia
8081 Innovation Park Dr, 765, Fairfax, VA 22031

Additional Areas of Focus

Dr. Guerrera has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients With Hemophilia A or B With Inhibitors
Enrollment Status: Recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drug: Coagulation factor VIIa [recombinant]-jncw
Study Phase: Phase 4
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease
Enrollment Status: Completed
Publish Date: May 15, 2026
Intervention Type: Biological
Study Drugs: Von Willebrand Factor, Factor VIII
Study Phase: Phase 3
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Genetic, Biological
Study Drug: AMT-061 Adeno-Associated Virus Padua Variant FIX Vaccine
Study Phase: Phase 3
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People With Hemophilia
Enrollment Status: Completed
Publish Date: February 12, 2025
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
US Cohort Study of Previously Untreated Patients (PUPs) With Congenital Hemophilia
Enrollment Status: Completed
Publish Date: February 01, 2023
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
View 5 Less Clinical Trials

17 Total Publications

Lack of Inhibitor Development in Previously Treated People With Haemophilia Switching Factor Products-Final Results of Athn 2: Factor Switching Study.
Lack of Inhibitor Development in Previously Treated People With Haemophilia Switching Factor Products-Final Results of Athn 2: Factor Switching Study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: January 17, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (3.4 miles away)
202-444-2223
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Craig Kessler is a Hematologist practicing medicine in Washington, Washington, D.c.. Dr. Kessler is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy. Dr. Kessler is currently accepting new patients.

Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Expertise in
18
conditions
Dr. Brigitte C. Widemann
Hematology | Oncology
Referral may be required

Office

8906 Bradmoor Dr, 
Bethesda, MD 
 (7.8 miles away)
301-496-7387
Languages Spoken:
English

Brigitte Widemann is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Widemann is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Medullary Thyroid Carcinoma, and Thyroidectomy.

Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Expertise in
16
conditions
Dr. Sharon A. Savage
Hematology | Oncology
Referral may be required

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (6.7 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Savage is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Aplastic Anemia, Pure Red Cell Aplasia, Congenital Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Michael F. Guerrera

How do I make an appointment with Dr. Michael F. Guerrera?

You can book an appointment with Dr. Michael F. Guerrera by calling their office at 202-476-5685. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Michael F. Guerrera a top-rated expert for Hemophilia A?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Michael F. Guerrera is classified as an Distinguished expert for Hemophilia A, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Michael F. Guerrera specialize in?

While Dr. Michael F. Guerrera is a Hematology, they have specific expertise in Hemophilia A, Blood Clots, and Hemophilia B. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Michael F. Guerrera participate in research or clinical trials?

Yes. Dr. Michael F. Guerrera has published 17 articles and abstracts on conditions like Hemophilia A. You can view a list of Dr. Michael F. Guerrera's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Michael F. Guerrera accept my insurance?

Dr. Michael F. Guerrera accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 202-476-5685 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Guerrera's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile